ABVC Stock Analysis: Buy, Sell, or Hold?
ABVC - ABVC BioPharma, Inc. Common Stock
$1.19
-0.12 (-9.16%)
▼
5d:
-10.53%
30d:
+11.21%
90d:
-6.3%
WAIT
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 20, 2026
0d
Get Alerted When ABVC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ABVC is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ABVC is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABVC is currently trading at $1.19, which is considered fair relative to its 30-day fair value range of $1.08 to $1.35.
Technical Outlook: Technically, ABVC is in a strong downtrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.02 (+69.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABVC is in a strong downtrend. The price is currently testing key support at $1.19. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.02 (+69.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.08 -
$1.35
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.2%)
- BULLISH: Trading 69.7% below Wall St target ($2.02)
- WARNING: Recommendation downgraded due to -10.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.19
Resistance Level
$1.48
Current Trend
Strong Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Wall Street Target
$2.02
(+69.7%)
Revenue Growth (YoY)
104.5%
Share & Embed Analysis
Last updated: June 15, 2026 8:23 AM ET
Data refreshes hourly during market hours. Next update: 9:23 AM
Data refreshes hourly during market hours. Next update: 9:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABVC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 63 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 51 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 52 HOLD |
